Active Surveillance in 2021 Part 2: Imaging and Biomarkers

Matthew Cooperberg, MD, MPH on Biomarkers in Prostate Cancer Active SurveillanceПодробнее

Active Surveillance 2021 - From Bench to BedsideПодробнее

Active Surveillance 2022: Who Qualifies, Who Does Not and How Should it be MonitoredПодробнее

Biomarkers to guide active surveillanceПодробнее

Navigating Prostate Cancer: Active Surveillance and Advanced Imaging InsightsПодробнее

Active Surveillance 2021 (Part 3) - Patient Selection, Monitoring, and Innocuous InterventionsПодробнее

Active Surveillance Results and Implications of Prospective StudiesПодробнее

Biomarkers’ Integration with Clinical Parameters, Imaging, and Prognostic InstrumentsПодробнее

Active Surveillance or: Shrinking the Gray ZoneПодробнее

Active Surveillance 101 – Part 2Подробнее

Biomarkers and ImagingПодробнее

Active Surveillance Conference Day 2Подробнее

What Role Do Markers Play in Establishing Active Surveillance or Definitive Care?Подробнее

Active Surveillance for Prostate CancerПодробнее

Active Surveillance in 2022 | Laurence Klotz, MD | PCRIПодробнее

Lecture 2. Regulatory view of imaging biomarkers for prostate cancer careПодробнее

Screening, Active Surveillance and Prostate Cancer BiomarkersПодробнее

Screening and Prevention of Prostate Cancer 2021 - Who Needs a Biopsy?Подробнее

Active Surveillance Criteria and Follow-up ProtocolПодробнее